- Home
- SIEB vs GLSI Comparison
SIEB vs GLSI Comparison
Compare SIEB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- GLSI
- Stock Information
- Founded
- SIEB 1886
- GLSI 2006
- Country
- SIEB United States
- GLSI United States
- Employees
- SIEB N/A
- GLSI N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- SIEB Finance
- GLSI Health Care
- Exchange
- SIEB Nasdaq
- GLSI Nasdaq
- Market Cap
- SIEB 126.1M
- GLSI 145.2M
- IPO Year
- SIEB N/A
- GLSI 2020
- Fundamental
- Price
- SIEB $2.90
- GLSI $8.20
- Analyst Decision
- SIEB
- GLSI Strong Buy
- Analyst Count
- SIEB 0
- GLSI 1
- Target Price
- SIEB N/A
- GLSI $39.00
- AVG Volume (30 Days)
- SIEB 17.7K
- GLSI 84.6K
- Earning Date
- SIEB 11-12-2025
- GLSI 11-14-2025
- Dividend Yield
- SIEB N/A
- GLSI N/A
- EPS Growth
- SIEB N/A
- GLSI N/A
- EPS
- SIEB 0.18
- GLSI N/A
- Revenue
- SIEB $90,289,000.00
- GLSI N/A
- Revenue This Year
- SIEB N/A
- GLSI N/A
- Revenue Next Year
- SIEB N/A
- GLSI N/A
- P/E Ratio
- SIEB $16.05
- GLSI N/A
- Revenue Growth
- SIEB 8.32
- GLSI N/A
- 52 Week Low
- SIEB $2.08
- GLSI $7.88
- 52 Week High
- SIEB $5.77
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- SIEB 47.81
- GLSI 33.78
- Support Level
- SIEB $2.70
- GLSI $7.94
- Resistance Level
- SIEB $2.91
- GLSI $8.55
- Average True Range (ATR)
- SIEB 0.17
- GLSI 0.59
- MACD
- SIEB 0.01
- GLSI 0.02
- Stochastic Oscillator
- SIEB 67.54
- GLSI 14.11
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.